SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that
Amit D. Munshi, President and Chief
Executive Officer of Arena, will present a corporate update at the
Cantor Global Healthcare Conference on Wednesday, October 2, at 3:00 PM EDT. The conference will take place
October 2-4, 2019, in New York City.
A live audio webcast of the presentation will be available under
the investor relations section of Arena's website at
www.arenapharm.com. A replay of the presentation will be available
for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology to patients globally. Arena's proprietary pipeline
includes multiple potentially first- or best-in-class assets with
broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune-mediated and inflammatory
conditions, is being evaluated in later-stage clinical programs in
ulcerative colitis (UC) and Crohn's disease (CD), as well as in
programs for other indications such as atopic dermatitis. Arena is
also evaluating olorinab (APD371) in a Phase 2 program for
gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's presentation and webcast of the investor
conference, Arena's drive, and the potential of Arena's assets,
programs, licenses, and partnerships. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-at-the-cantor-global-healthcare-conference-on-october-2-300924762.html
SOURCE Arena Pharmaceuticals, Inc.